Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une étude premier humaine pour savoir à quel point la baie 3713372 est sûre et comment elle fonctionne chez les participants avec des tumeurs solides supprimées par le MTAP

10 novembre 2026 mis à jour par: Bayer

Une étude de premier humaine pour évaluer la sécurité, la tolérabilité et la pharmacocinétique, la pharmacodynamique et l'activité clinique préliminaire de la baie 3713372, un nouvel inhibiteur de PRMT5 de 2e génération, chez les participants avec des tumeurs solides supprimées par MTAP.

The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-deleted cancer cells while sparing the normal cells.

The main objective of this first-in-human study is to learn how safe BAY 3713372 is, how the body processes it, and how well it works in people with MTAP-deleted solid tumors.

For this, the researchers will study and analyze:

  • the number of participants who have adverse events (AEs) after receiving different doses of BAY 3713372 and the AE's severity.
  • the number of participants who experience dose-limiting toxicities (DLTs) after receiving different doses of BAY 3713372, the DLT's severity and how often they happened. A DLT is a pre-defined medical problem caused by a specific dose of a drug that is too severe to continue using that dose.
  • the total amount of BAY 3713372 in participants' blood (also called AUC) over time after single and multiple doses.
  • the highest level of BAY 3713372 in participants' blood (also called Cmax) after single and multiple doses.

Other than the main objective, researchers will also check for the number of participants who show a response to treatment and how long they live without the cancer getting worse.

The study participants will take part in one of the eight distinct groups or "intervention cohorts" of the study. The study will start with a dose escalation phase where distinct groups of participants will receive different doses of BAY 3713372 alone to find the dose that is deemed safe and works best for the participants. When this dose has been found, a larger number of participants will receive BAY 3713372 alone or with other treatments in a dose expansion phase.

Participants may take the study treatment as long as they benefit from the treatment without any severe medical problems.

Participants will visit the study site:

  • at least twice before the treatment starts
  • multiple times when they start taking the treatment
  • once after 30 days of receiving the last dose and every 9 weeks after that until the cancer worsens, or the participant stops for any other reason

During the study, the doctors and their study team will:

  • check participants' health by performing tests such as blood and urine tests, and checking heart health using an electrocardiogram
  • check if the participants' cancer has grown and/or spread using computed tomography (CT) or magnetic resonance imaging (MRI) and, if needed, bone scan
  • take tumor samples

The study doctors and their team will contact the participants every 3 months until 2 years after the last participant's last dose or the end of the study to learn about the participant's health.

Aperçu de l'étude

Statut

Recrutement

Intervention / Traitement

Type d'étude

Interventionnel

Inscription (Estimé)

450

Phase

  • Phase 2
  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • New South Wales
      • Camperdown, New South Wales, Australie, 2050
        • Recrutement
        • Chris O'Brien Lifehouse
      • Concord, New South Wales, Australie, 2139
        • Recrutement
        • Concord Repatriation General Hospital (CRGH) (Concord Hospital) - Concord Cancer Centre
      • Epping, New South Wales, Australie, 3076
        • Pas encore de recrutement
        • Northern Hospital
      • Waratah, New South Wales, Australie, 2298
        • Recrutement
        • Calvary Mater Hospital Newcastle - Oncology
    • Antwerp
      • Antwerp, Antwerp, Belgique, 2650
        • Recrutement
        • Antwerp University Hospital | Oncology Department
    • East Flanders
      • Ghent, East Flanders, Belgique, 9000
        • Recrutement
        • Ghent University Hospital | Drug Research Unit Department
    • Flemish Brabant
      • Leuven, Flemish Brabant, Belgique, 3000
        • Recrutement
        • UZ Leuven Gasthuisberg - Pneumology Department
    • Liège
      • Liège, Liège, Belgique, 4000
        • Recrutement
        • Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman - Medical Oncology
    • Beijing Municipality
      • Beijing, Beijing Municipality, Chine, 100142
        • Recrutement
        • Beijing Cancer Hospital - Oncology Department
      • Beijing, Beijing Municipality, Chine, 101149
        • Pas encore de recrutement
        • Beijing chest hospital, Capital Medical University
    • Hubei
      • Wuhan, Hubei, Chine, 430075
        • Recrutement
        • Tongji Hosp. of Tongji Med Coll, Huazhong Uni of Sci & Tech.
    • Jiangsu
      • Nanjing, Jiangsu, Chine, 210029
        • Pas encore de recrutement
        • Jiangsu Provincial People's Hospital - The First Affiliated Hospital of Nanjing Medical University
    • Zhejiang
      • Hangzhou, Zhejiang, Chine, 310016
        • Pas encore de recrutement
        • Sir Run Run Shaw Hospital, Zhejiang Univ. School of Medicine - Oncology Department
    • Capital Region / Region Hovedstaden
      • Copenhagen, Capital Region / Region Hovedstaden, Danemark, 2100
        • Recrutement
        • Rigshospitalet Copenhagen University Hospital | Oncology Department
    • Region of Southern Denmark / Region Syddanmark
      • Odense, Region of Southern Denmark / Region Syddanmark, Danemark, 5000
        • Recrutement
        • Odense University Hospital | Svendborg Sygehus - Oncology Department
    • Barcelona
      • Barcelona, Barcelona, Espagne, 08023
        • Recrutement
        • Hospital Hm Nou Delfos | Oncologia
      • Barcelona, Barcelona, Espagne, 08035
        • Recrutement
        • Hospital Universitari Vall D Hebron | Oncologia
    • Chartered Community of Navarre
      • Pamplona, Chartered Community of Navarre, Espagne, 31008
        • Recrutement
        • Clinica Universidad De Navarra | Pamplona | Oncologia
    • La Rioja
      • Logroño, La Rioja, Espagne, 26006
        • Recrutement
        • Hospital San Pedro | Oncologia
    • Madrid
      • Madrid, Madrid, Espagne, 28040
        • Recrutement
        • Hospital Universitario Fundacion Jimenez Diaz | Oncologia
      • Pozuelo de Alarcón, Madrid, Espagne, 28223
        • Recrutement
        • NEXT - Hospital Universitario Quironsalud Madrid | Oncologia
    • Málaga
      • Málaga, Málaga, Espagne, 29010
        • Recrutement
        • Hospital Universitario Virgen De La Victoria | Oncologia
    • Valencia
      • Valencia, Valencia, Espagne, 46010
        • Pas encore de recrutement
        • Hospital Clinico Universitario De Valencia | Oncologia
    • Friuli Venezia Giulia
      • Aviano, Friuli Venezia Giulia, Italie, 33081
        • Recrutement
        • Centro di Riferimento Oncologico di Aviano - Oncologia Medica e dei Tumori Immuno-Correlati
    • Lazio
      • Rome, Lazio, Italie, 00128
        • Recrutement
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Fase I
      • Rome, Lazio, Italie, 00144
        • Pas encore de recrutement
        • I.F.O. Istituti Fisioterapici Ospitalieri - Sperimentazioni cliniche Fase 1 e Medicina di precisione
    • Lombardy
      • Milan, Lombardy, Italie, 20133
        • Recrutement
        • Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Oncologia Medica 1
      • Rozzano, Lombardy, Italie, 20089
        • Recrutement
        • Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia
    • Aichi-ken
      • Nagoya, Aichi-ken, Japon, 466-8560
        • Pas encore de recrutement
        • Nagoya University Hospital
    • Osaka
      • Sakai, Osaka, Japon, 590-0197
        • Recrutement
        • Kindai University Hospital
    • Shizuoka
      • Sunto, Shizuoka, Japon, 411-8777
        • Recrutement
        • Shizuoka Cancer Center
    • Tokyo
      • Chuo-ku, Tokyo, Japon, 104-0045
        • Recrutement
        • National Cancer Center Hospital
      • Koto-ku, Tokyo, Japon, 135-8550
        • Recrutement
        • The Cancer Institute Hospital of JFCR
    • North Holland
      • Amsterdam, North Holland, Pays-Bas, 1066 CX
        • Recrutement
        • Nederlands Kanker Instituut
    • Provincie Groningen
      • Groningen, Provincie Groningen, Pays-Bas, 9713 GZ
        • Pas encore de recrutement
        • Universitair Medisch Centrum Groningen (UMCG) - UMC Groningen Comprehensive Cancer Center
    • South Holland
      • Rotterdam, South Holland, Pays-Bas, 3015 CE
        • Recrutement
        • Erasmus Medisch Centrum
    • Greater Manchester
      • Manchester, Greater Manchester, Royaume-Uni, M20 4BX
        • Recrutement
        • The Christie Hospital | Experimental Cancer Medicine Team
    • Surrey
      • Sutton, Surrey, Royaume-Uni, SM2 5PT
        • Pas encore de recrutement
        • The Royal Marsden (Surrey) | Oak Foundation Drug Development Unit
    • Singapore
      • Singapore, Singapore, Singapour, 119074
        • Recrutement
        • National University Hospital Medical Centre
      • Singapore, Singapore, Singapour, 168583
        • Recrutement
        • National Cancer Center Singapore - Oncology Department
      • Singapore, Singapore, Singapour, 217562
        • Recrutement
        • Icon Cancer Centre
    • Stockholm County
      • Stockholm, Stockholm County, Suède, 171 76
        • Recrutement
        • Karolinska Universitetssjukhuset - Solna - Fas I-enheten Solna CKC
    • Västra Götaland County
      • Gothenburg, Västra Götaland County, Suède, 413 46
        • Pas encore de recrutement
        • Sahlgrenska Universitetssjukhuset - Sahlgrenska Sjukhuset - Klinisk prövningsenhet Fas I/FIH
    • Olomouc Region
      • Olomouc, Olomouc Region, Tchéquie, 779 00
        • Recrutement
        • Fakultní nemocnice Olomouc - Onkologická klinika
    • South Moravian
      • Brno, South Moravian, Tchéquie, 602 00
        • Recrutement
        • Masarykova Univerzita - Masarykuv Onkologicky Ustav (MOU) - Klinika Komplexni Onkologicke Pece (KKOP)
    • Alabama
      • Birmingham, Alabama, États-Unis, 35233
        • Pas encore de recrutement
        • UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital
    • California
      • Duarte, California, États-Unis, 91010
        • Pas encore de recrutement
        • City of Hope - Duarte Cancer Center
      • Los Angeles, California, États-Unis, 90095
        • Pas encore de recrutement
        • UCLA Health Bowyer Oncology Center
      • San Francisco, California, États-Unis, 94143
        • Recrutement
        • UCSF Helen Diller Medical Center at Parnassus Heights - Neurology
      • Stanford, California, États-Unis, 94305
        • Pas encore de recrutement
        • Stanford University Medical Center - Neurology
    • Colorado
      • Aurora, Colorado, États-Unis, 80045
        • Pas encore de recrutement
        • UCHealth Cancer Center - Anschutz Medical Campus - University of Colorado Cancer Center
      • Denver, Colorado, États-Unis, 80218
        • Recrutement
        • Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's
    • Florida
      • Orlando, Florida, États-Unis, 32827
        • Recrutement
        • Sarah Cannon Research Institute at Florida Cancer Specialists- Lake Nona
    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02215
        • Pas encore de recrutement
        • Dana-Farber Cancer Institute - Oncology Department
      • Boston, Massachusetts, États-Unis, 02114
        • Recrutement
        • Massachusetts General Hospital - Neurology
    • Michigan
      • Grand Rapids, Michigan, États-Unis, 49546
        • Recrutement
        • START | Midwest
    • New York
      • New York, New York, États-Unis, 10065
        • Recrutement
        • Memorial Sloan Kettering Cancer Center New York - Main Campus
      • New York, New York, États-Unis, 10029
        • Recrutement
        • Icahn School of Medicine at Mount Sinai - Oncology
    • Tennessee
      • Nashville, Tennessee, États-Unis, 37203
        • Recrutement
        • SCRI Oncology Partners
    • Texas
      • Irving, Texas, États-Unis, 75039
        • Recrutement
        • NEXT Dallas - Oncology Department
      • San Antonio, Texas, États-Unis, 78229
        • Recrutement
        • START | San Antonio
    • Wisconsin
      • Milwaukee, Wisconsin, États-Unis, 53226
        • Pas encore de recrutement
        • Froedtert Hospital - Clinical Cancer Center

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Participant must be ≥ 18 years old of age, or the legal age of consent in the jurisdiction of the country in which the study takes place, at the time of signing the informed consent.
  • At least one measurable lesion that would qualify as target lesion by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).
  • Homozygous MTAP-deletion identified through molecular testing from a locally certified laboratory.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Exclusion Criteria:

  • Previous additional cancer other than the one evaluated in this study within the past 2 years except for basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, superficial bladder tumors, localized prostate cancer or other tumors that in the opinion of the investigator, are considered cured or not immediately life-threatening, and will not interfere with the scientific goals of this study.

  • A marked prolongation of QT/QTc interval at screening (e.g., repeated demonstration of a QTc interval >450 ms). Participants with permanent pacemakers (i.e., a paced rhythm) may be eligible based on the investigator's clinical assessment and discretion.

  • Cardiac history comprising:

    • History of congestive heart failure Class >II according to the New York Heart Association Functional Classification.
    • Myocardial infarction less than 6 months before the start of study intervention.
    • Serious cardiac arrhythmias requiring treatment or any clinically important abnormalities in rhythm, conduction or morphology on resting ECG with the exception of atrial fibrillation which is well-controlled and requires only digoxin or beta blockers.
  • Unstable angina within 4 weeks before start of study intervention.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Non randomisé
  • Modèle interventionnel: Affectation séquentielle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Dose Escalation (Intervention Cohort 1)

For the escalation part, different dose levels of BAY 3713372 administered as monotherapy are planned.

Daily oral administration

Expérimental: Backfill cohorts in Intervention Cohort 1 (Dose Escalation)

Backfill cohorts may be initiated concurrently with dose escalation cohorts to generate additional safety, pharmacokinetic, and pharmacodynamic data to facilitate the selection of the optimal doses for use in further development.

Daily oral administration

Expérimental: Dose Expansion (Intervention Cohort 1)

Dose expansion with BAY 3713372 monotherapy in selected participants with MTAP-deleted solid tumors.

Daily oral administration

Expérimental: Dose Expansion (Intervention Cohort 2)

Dose expansion with BAY 3713372 monotherapy in participants with MTAP-deleted non-small cell lung cancer (NSCLC).

Daily oral administration

Expérimental: Dose Expansion (Intervention Cohort 3)

Dose expansion with BAY 3713372 in combination with other treatments in participants with MTAP-deleted NSCLC.

Daily oral administration

Expérimental: Dose Expansion (Intervention Cohort 4)

Dose expansion with BAY 3713372 in combination with other treatments in participants with MTAP-deleted NSCLC.

Daily oral administration

Expérimental: Dose Expansion (Intervention Cohort 5)

Dose expansion with BAY 3713372 monotherapy in participants with MTAP-deleted pancreatic ductal adenocarcinoma (PDAC).

Daily oral administration

Expérimental: Dose Expansion (Intervention Cohort 6)

Dose expansion with BAY 3713372 in combination with other treatments in participants with MTAP-deleted PDAC.

Daily oral administration

Expérimental: Window-of-opportunity trial in participants with MTAP-deleted GBM (Intervention Cohort 7)

A surgical window-of-opportunity trial of BAY 3713372 alone in participants with MTAP-deleted glioblastoma (GBM).

Daily oral administration

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Escalade de dose (cohorte maître et intervention 1): concentration maximale (CMAX) de l'intervalle de dosage respectif de la baie 3713372
Délai: Depuis la première dose d'intervention d'étude jusqu'au cycle 2 jour 1 (chaque cycle est de 21 jours)
Depuis la première dose d'intervention d'étude jusqu'au cycle 2 jour 1 (chaque cycle est de 21 jours)
Escalade de dose (maître et intervention cohorte 1): zone sous la courbe (AUC) de l'intervalle de dosage respectif de la baie 3713372
Délai: Depuis la première dose d'intervention d'étude jusqu'au cycle 2 jour 1 (chaque cycle est de 21 jours)
Depuis la première dose d'intervention d'étude jusqu'au cycle 2 jour 1 (chaque cycle est de 21 jours)
Dose Escalation (Master and Intervention Cohort 1): Number of participants with treatment-emergent adverse events (TEAEs)
Délai: From the first administration of study intervention up to 30 days after the last dose of study intervention

TEAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

From the first administration of study intervention up to 30 days after the last dose of study intervention
Dose Escalation (Master and Intervention Cohort 1): Number of participants with treatment-emergent serious adverse events (TESAEs)
Délai: From the first administration of study intervention up to 30 days after the last dose of study intervention

TESAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

From the first administration of study intervention up to 30 days after the last dose of study intervention
Dose Escalation (Master and Intervention Cohort 1): Severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)
Délai: From the first administration of study intervention up to 30 days after the last dose of study intervention

TEAEs and TESAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

From the first administration of study intervention up to 30 days after the last dose of study intervention
Dose Escalation (Master and Intervention Cohort 1): Incidence of dose-limiting toxicities (DLTs)
Délai: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)

DLTs per participants. DLTs will be graded according to NCI-CTCAE v.5.0

From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)
Dose Escalation (Master and Intervention Cohort 1): Number of participants with DLTs
Délai: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)

Number of participants with at least one DLT

From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)
Dose Expansion (Master, Intervention Cohorts 1 - 6): Objective response rate (ORR)
Délai: Approximately 1.5 years

Determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)

Approximately 1.5 years
Dose Expansion (Intervention Cohorts 3, 4 and 6): Number of participants with DLTs
Délai: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days, except for Intervention Cohort 6, which has a cycle length of 28 days)

Number of participants with at least one DLT

From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days, except for Intervention Cohort 6, which has a cycle length of 28 days)
Intervention Cohort 7: Number of participants with treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)
Délai: From the first administration of study intervention up to 30 days after the last dose of study intervention

TEAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

From the first administration of study intervention up to 30 days after the last dose of study intervention
Intervention Cohort 7: Severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)
Délai: From the first administration of study intervention up to 30 days after the last dose of study intervention

TEAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

From the first administration of study intervention up to 30 days after the last dose of study intervention
Intervention Cohort 7: Number of participants with DLTs
Délai: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)

Number of participants with at least one DLT

From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)
Intervention Cohort 7: Brain and brain tumor PK concentration of BAY 3713372
Délai: From first dose through day of surgery (approximately 7 ± 2 days)

Concentration of BAY 3713372 in enhancing and non-enhancing brain tumor tissue obtained at definitive surgery, with corresponding time-matched plasma concentrations and estimation of tumor-to-plasma exposure ratios

From first dose through day of surgery (approximately 7 ± 2 days)
Intervention Cohort 7: Tumor tissue SDMA levels
Délai: From first dose through day of surgery (approximately 7 ± 2 days)

Change in symmetric dimethylarginine (SDMA) levels in brain tumor tissue collected at definitive surgery following neoadjuvant BAY 3713372 treatment, as a pharmacodynamic marker of PRMT5 inhibition

From first dose through day of surgery (approximately 7 ± 2 days)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Escalade de dose (maître et intervention cohorte 1): Temps de réponse (TTR)
Délai: Environ 1,5 ans
Environ 1,5 ans
Expansion de la dose (maître, cohortes d'intervention 1 à 6): temps de réponse (TTR)
Délai: Environ 1,5 ans
Environ 1,5 ans
Expansion de la dose (maître, cohortes d'intervention 1 à 4 et 6): concentration maximale (CMAX) de l'intervalle de dosage respectif de la baie 3713372
Délai: Depuis la première dose d'intervention d'étude jusqu'au cycle 2 jour 1 (chaque cycle est de 21 jours, à l'exception de l'intervention Cohort 6, qui a une durée de cycle de 28 jours)
Depuis la première dose d'intervention d'étude jusqu'au cycle 2 jour 1 (chaque cycle est de 21 jours, à l'exception de l'intervention Cohort 6, qui a une durée de cycle de 28 jours)
Expansion de la dose (maître, cohortes d'intervention 1 à 4 et 6): zone sous la courbe (AUC) de l'intervalle de dosage respectif de la baie 3713372
Délai: Depuis la première dose d'intervention d'étude jusqu'au cycle 2 jour 1 (chaque cycle est de 21 jours, à l'exception de l'intervention Cohort 6, qui a une durée de cycle de 28 jours)
Depuis la première dose d'intervention d'étude jusqu'au cycle 2 jour 1 (chaque cycle est de 21 jours, à l'exception de l'intervention Cohort 6, qui a une durée de cycle de 28 jours)
Dose Expansion (Part A of Intenvention Cohort 2): Time to CNS progression (CNS-TTP)
Délai: Approximately 3 years
Approximately 3 years
Dose Expansion (Part B of Intervention Cohort 2): CNS-related disease control rate (CNS-DCR) in active brain metastases
Délai: Approximately 1.5 years
Approximately 1.5 years
Dose Escalation (Master and Intervention Cohort 1): Objective response rate (ORR)
Délai: Approximately 1.5 years

Determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)

Approximately 1.5 years
Dose Escalation (Master and Intervention Cohort 1): Duration of response (DOR)
Délai: Approximately 3 years

Determined by the investigator according to RECIST v1.1

Approximately 3 years
Dose Escalation (Master and Intervention Cohort 1): Progression-free survival (PFS)
Délai: Approximately 3 years

Determined by the investigator according to RECIST v1.1

Approximately 3 years
Dose Expansion (Master, Intervention Cohorts 1 - 6): Number of participants with treatment-emergent adverse events (TEAEs)
Délai: From the first administration of study intervention up to 30 days after the last dose of study intervention

TEAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

From the first administration of study intervention up to 30 days after the last dose of study intervention
Dose Expansion (Master, Intervention Cohorts 1 - 6): Number of participants with treatment-emergent serious adverse events (TESAEs)
Délai: From the first administration of study intervention up to 30 days after the last dose of study intervention

TESAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

From the first administration of study intervention up to 30 days after the last dose of study intervention
Dose Expansion (Master, Intervention Cohorts 1 - 6): Severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)
Délai: From the first administration of study intervention up to 30 days after the last dose of study intervention

TEAEs and TESAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

From the first administration of study intervention up to 30 days after the last dose of study intervention
Dose Expansion (Master, Intervention Cohorts 1, 3, 4, and 6): Incidence of dose-limiting toxicities (DLTs)
Délai: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days, except for Intervention Cohort 6, which has a cycle length of 28 days)

DLTs per participants. DLTs will be graded according to NCI-CTCAE v.5.0

From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days, except for Intervention Cohort 6, which has a cycle length of 28 days)
Dose Expansion (Master, Intervention Cohorts 1 - 6): Duration of response (DOR)
Délai: Approximately 3 years

Determined by the investigator according to RECIST v1.1

Approximately 3 years
Dose Expansion (Master, Intervention Cohorts 1 - 6): Progression-free survival (PFS)
Délai: Approximately 3 years

Determined by the investigator according to RECIST v1.1

Approximately 3 years
Dose Expansion (Part B of Intervention Cohort 2): CNS-ORR for active brain metastases
Délai: Approximately 1.5 years

CNS-ORR: CNS objective response rate

Approximately 1.5 years
Dose Expansion (Part B of Intervention Cohort 2): CNS-DOR for active brain metastases
Délai: Approximately 3 years

CNS-DOR: Duration of CNS response

Approximately 3 years
Dose Expansion (Part B of Intervention Cohort 2): CNS-PFS for active brain metastases
Délai: Approximately 3 years

CNS-PFS: Survival without CNS progression

Approximately 3 years
Dose Expansion (Part B of Intervention Cohort 2): CNS-TTR for active brain metastases
Délai: Approximately 1.5 years

CNS-TTR: Time to CNS response

Approximately 1.5 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

21 mars 2025

Achèvement primaire (Estimé)

18 juin 2029

Achèvement de l'étude (Estimé)

18 juin 2029

Dates d'inscription aux études

Première soumission

31 mars 2025

Première soumission répondant aux critères de contrôle qualité

31 mars 2025

Première publication (Réel)

6 avril 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

12 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

10 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner